Conference Proceedings

Influence of baseline demographic characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a phase 2, randomized, placebo-controlled trial

Melinda Gooderham, Kim Papp, Kenneth Gordon, Peter Foley, Akimichi Morita, Subhashis Banerjee, Sudeep Kundu, Renata Kisa, Andrew Napoli, Diamant Thaci

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | MOSBY-ELSEVIER | Published : 2019

Grants

Funding Acknowledgements

Supported by Bristol-Myers Squibb.